Skip to main content

Table 1. Summary of cases available in the literature that used venetoclax in BPDCN

From: Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature

Study

N

Median age

Median previous lines

Added treatments

Type of response

Max. duration of response

Follow-up

Grushchak et al. Medicine (2017)[8]

1

65

2

No

CR

>10 months

10 months

Montero et al. Cancer Discov. (2017)[7]

2

76,5

3

No

PR

4 weeks

Until death

DiNardo et al. Am J Hematol. (2018)[5]

2

74,5

3

Yes, NR but probably HMA or LDAC

CR/PR

NR

NR

Agha et al. N Engl J Med. (2018)[10]

1

62

4

No

CR

>9 months

9 months

Beziat et al. Leuk Res. (2019)[11]

1

77

1

No

PR

1 month

NR

Piccini et al. Ann Hematol. (2020)[12]

1

64

2

Azacitidine

CR

>11 months

11 months

Samhouri et al. J Oncol Pharm Pract. (2020)[13]

1

79

1

Azacitidine

PR

>6 months

6 months

Albiol et al. J Med Case Rep. (2021)

1

54

4 plus intrathecal therapy

No

PR

3 months

Until death

  1. CR complete response, PR partial response, NR not reported, HMA hypomethylating agent, LDAC low-dose ara-C